In our study, we observed that the ENPP2 targeted inhibitor PF-8380 exhibited positive antidrug resistance in CLL-targeted drug sensitivities, such as Ibrutinib, thus providing new prospects for clinical chemotherapy resistance. The gene discussed is ENPP2; the disease is B-cell chronic lymphocytic leukemia.